<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">eef1a1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>EEF1A1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>eef1a1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=EEF1A1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">71 edges</a></td>
</tr>
</table>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">eef1a1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>EEF1A1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>eef1a1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=EEF1A1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">71 edges</a></td>
</tr>
</table>
Eukaryotic Translation Elongation Factor 1 Alpha 1 (EEF1A1) is one of the most abundant and evolutionarily conserved proteins in eukaryotic cells, serving as the essential mediator of aminoacyl-tRNA delivery to the ribosome during the elongation phase of protein synthesis. Beyond its canonical role in translation, EEF1A1 has emerged as a multifunctional protein with critical roles in cytoskeletal organization, signal transduction, apoptosis regulation, and stress response pathways.[@m2014] These diverse functions position EEF1A1 as a crucial player in neuronal homeostasis and, consequently, in the pathogenesis of major neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and related proteinopathies.
The dysregulation of EEF1A1 has been increasingly recognized as a common thread linking translational dysfunction to neurodegeneration.[@p2020] Studies have demonstrated that alterations in EEF1A1 expression, post-translational modification, and subcellular localization contribute to the molecular cascades underlying neuronal death in both Alzheimer's and Parkinson's disease contexts.[@s2023] This page provides a comprehensive overview of EEF1A1's structure, molecular functions, cellular roles, and its implications in neurodegenerative disease pathogenesis.
The EEF1A1 gene (Ensembl ID: ENSG00000156508, NCBI Gene ID: 1915) is located on chromosome 6q13 and encodes a 462-amino acid protein with a molecular weight of approximately 50 kDa. The gene consists of multiple exons and is transcribed by RNA polymerase II under the control of various promoter elements that respond to cellular growth conditions, stress signals, and developmental cues. EEF1A1 is part of a family of translation elongation factors that includes the closely related isoform EEF1A2, which is expressed predominantly in muscle and neuronal tissues and can partially compensate for EEF1A1 loss in certain contexts.
EEF1A1 adopts a characteristic three-dimensional structure consisting of multiple domains optimized for its interactions with GTP, aminoacyl-tRNA, and the ribosomal complex. The protein possesses a GTP-binding domain (Domain I) that undergoes conformational changes upon GTP hydrolysis, driving the delivery of aminoacyl-tRNA to the ribosomal A-site. Domains II and III form a beta-barrel structure that facilitates interactions with the ribosome and various regulatory proteins. Post-translational modifications including phosphorylation, acetylation, and methylation modulate EEF1A1's activity and subcellular localization in response to cellular signals.
During the elongation phase of translation, EEF1A1 forms a ternary complex with GTP and aminoacyl-tRNA, delivering the charged tRNA to the ribosomal A-site in a GTP-dependent manner. Upon successful codon-anticodon pairing, GTP hydrolysis triggers the conformational change that releases EEF1A1•GDP from the ribosome, allowing the peptidyl transferase center to catalyze peptide bond formation. The GDP-bound EEF1A1 is then recycled to its active GTP-bound form through the action of the exchange factor eEF1B, completing the cycle. This process repeats for each amino acid added to the growing polypeptide chain, making EEF1A1 essential for all protein synthesis beyond the initiation phase.
The activity of EEF1A1 is tightly regulated at multiple levels to ensure accurate and efficient protein synthesis. Autophosphorylation of EEF1A1 enhances its affinity for aminoacyl-tRNA, while kinase-mediated phosphorylation in response to cellular signals modulates its activity. The availability of aminoacyl-tRNAs, particularly those for rare codons, influences the rate of elongation and can cause ribosome stalling when dysregulated. Additionally, EEF1A1 interacts with various RNA-binding proteins and translation factors that coordinate the elongation process with other cellular pathways, creating an integrated system for protein synthesis control.
EEF1A1 associates with actin filaments and microtubules, where it participates in cytoskeletal organization and dynamics. This function is mediated through direct interactions with actin and tubulin monomers, as well as through binding to various cytoskeletal regulatory proteins. In neuronal cells, EEF1A1's cytoskeletal role is particularly important for maintaining axonal and dendritic integrity, supporting synaptic plasticity, and facilitating intracellular transport. The cytoskeletal functions of EEF1A1 are especially relevant to neurodegeneration, as cytoskeletal disruption is a hallmark of many neurodegenerative conditions.
Beyond its role in translation, EEF1A1 functions as a signaling molecule that participates in various signal transduction cascades. It interacts with components of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, the mitogen-activated protein kinase (MAPK) cascade, and other signaling networks that control cell growth, survival, and death. These interactions position EEF1A1 at the interface between translational control and cellular signaling, allowing it to coordinate protein synthesis with growth factor signaling and stress responses.
EEF1A1 plays complex roles in the regulation of apoptosis, with both pro-survival and pro-apoptotic functions depending on cellular context and post-translational modifications.[@cm2009] In some contexts, EEF1A1 promotes cell survival through its translational functions and through direct interactions with anti-apoptotic proteins. In others, it can facilitate apoptosis through its interactions with p53 and other pro-apoptotic factors. This duality is relevant to neurodegeneration, where both insufficient removal of damaged neurons and excessive cell death contribute to disease pathology.
Under cellular stress conditions such as oxidative stress, heat shock, or nutrient deprivation, EEF1A1 localizes to stress granules—membrane-less organelles that sequester translation initiation complexes and mRNAs when global translation is inhibited. Stress granule formation represents a protective response that conserves cellular resources and facilitates recovery after stress. However, persistent stress granule formation and impaired dissolution have been implicated in neurodegenerative diseases, where abnormal stress granule dynamics may contribute to proteostatic failure and neuronal dysfunction.
EEF1A1 is one of the most abundantly expressed genes in virtually all eukaryotic cells, with protein levels often comprising 1-5% of total cellular protein. In the human brain, EEF1A1 shows particularly high expression in neurons across all major brain regions. Within neurons, EEF1A1 is enriched in both the soma and synaptic compartments, reflecting its essential role in local protein synthesis that supports synaptic plasticity and function. The protein is expressed in all major neuron types, including excitatory glutamatergic neurons, inhibitory GABAergic neurons, and various neuromodulatory neuron populations.
Beyond its predominant cytoplasmic localization, EEF1A1 has been detected in various cellular compartments including the nucleus, mitochondria, and synaptic vesicles. Nuclear EEF1A1 may participate in nuclear export processes and transcriptional regulation, while mitochondrial association suggests potential roles in mitochondrial translation and function. Synaptic vesicle localization indicates involvement in presynaptic protein synthesis and synaptic transmission. This subcellular distribution is dynamic and can change in response to cellular conditions, with altered localization observed in various disease states.
In [Alzheimer's disease](/diseases/alzheimers-disease), EEF1A1 dysregulation contributes to the translational defects that characterize the disease brain. Post-mortem studies have revealed altered EEF1A1 expression and phosphorylation patterns in Alzheimer's disease tissue compared to age-matched controls. The protein interacts with tau pathology, with EEF1A1 found in association with neurofibrillary tangles composed of hyperphosphorylated tau. This association may reflect disrupted axonal transport and impaired local translation in affected neurons, contributing to synaptic loss and neuronal degeneration.
The amyloid-beta peptide, the aggregation-prone protein that forms extracellular plaques in Alzheimer's disease, directly affects EEF1A1 function and localization. Amyloid-beta exposure leads to altered EEF1A1 phosphorylation and impaired translational capacity in neuronal cells, creating a feedforward loop where amyloid pathology disrupts protein synthesis homeostasis. Furthermore, EEF1A1's role in stress granule dynamics may be relevant to the formation of stress granule-like inclusions observed in Alzheimer's disease brains.
Translational dysregulation is increasingly recognized as a central feature of Alzheimer's disease pathogenesis. Ribosome profiling studies have identified widespread changes in translation efficiency in Alzheimer's disease brain, with specific mRNA subsets showing particularly altered translation. EEF1A1, as a key regulator of the elongation phase, is positioned to contribute to these defects. The involvement of EEF1A1 in Alzheimer's disease extends to its interactions with various disease-associated proteins and pathways, including the mechanistic target of rapamycin (mTOR) signaling pathway, which is commonly dysregulated in the disease.
In [Parkinson's disease](/diseases/parkinsons-disease), EEF1A1 is implicated in multiple aspects of pathogenesis, from alpha-synuclein biology to mitochondrial dysfunction. Alpha-synuclein, the protein that forms Lewy bodies in Parkinson's disease brains, has been shown to interact with EEF1A1 and modulate its function. This interaction may contribute to the translational defects observed in Parkinson's disease brain and in cellular and animal models of the disease.
The dopaminergic neurons of the substantia nigra, which are particularly vulnerable in Parkinson's disease, show altered expression of translation factors including EEF1A1. This vulnerability may stem from the high translational demands of these neurons and their reliance on precise proteostatic mechanisms. EEF1A1 dysregulation in dopaminergic neurons may contribute to the progressive loss of these cells that characterizes Parkinson's disease.
Mitochondrial dysfunction is a hallmark of Parkinson's disease, and EEF1A1's roles in both mitochondrial translation and stress response are relevant to this aspect of pathogenesis. EEF1A1 participates in mitochondrial protein synthesis and is recruited to damaged mitochondria in response to cellular stress. Impaired EEF1A1 function may therefore contribute to the mitochondrial defects that drive dopaminergic neuron loss in Parkinson's disease.
Beyond Alzheimer's and Parkinson's disease, EEF1A1 dysfunction has been implicated in various other neurodegenerative and neurodevelopmental conditions. Mutations in EEF1A1 have been associated with neurodevelopmental disorders presenting with intellectual disability, cerebellar atrophy, and other neurological features, confirming the essential nature of EEF1A1 for proper neuronal development and function. These genetic studies provide direct evidence for EEF1A1's importance in the nervous system.
In amyotrophic lateral sclerosis (ALS), EEF1A1 dysregulation contributes to the translational defects and stress granule abnormalities observed in affected neurons. Similarly, in frontotemporal dementia, alterations in translation factors including EEF1A1 have been documented. The involvement of EEF1A1 across multiple neurodegenerative conditions underscores its fundamental importance for neuronal homeostasis.
EEF1A1 participates in ribosome-associated quality control (RQC) pathways that monitor translation fidelity and resolve stalled ribosomes. When ribosomes stall during translation due to problematic mRNA sequences, stalled nascent peptides, or ribosomal collisions, specialized quality control mechanisms target the stalled complexes for disassembly and recycling. EEF1A1's interactions with RQC components facilitate the resolution of stalled translation complexes, preventing the accumulation of potentially toxic incomplete translation products.
In neurodegenerative diseases, RQC pathways are often overwhelmed or dysregulated, leading to the accumulation of stalled ribosomes and incomplete translation products. This defect may be particularly damaging in neurons, which are post-mitotic and cannot dilute out damaged components through cell division. EEF1A1 dysfunction may therefore contribute to the proteostatic failure that characterizes many neurodegenerative conditions.
Synaptic plasticity, the cellular basis for learning and memory, requires rapid local protein synthesis at synapses in response to activity. EEF1A1 is enriched at synapses and participates in activity-dependent translation that supports long-term changes in synaptic strength. This function is mediated through regulation of EEF1A1 activity by synaptic signaling pathways and through interactions with synaptic RNA granules that transport translation machinery to distal neuronal compartments.
The dysregulation of synaptic translation is a consistent finding in neurodegenerative diseases, where synaptic loss is a major correlate of cognitive decline. EEF1A1 dysfunction may contribute to synaptic failure in Alzheimer's disease, Parkinson's disease, and related conditions, accelerating the loss of synaptic connectivity that underlies disease progression.
EEF1A1 functions within the broader cellular proteostasis network that includes protein synthesis, folding, degradation, and quality control pathways. Its integration with the proteostasis network means that EEF1A1 dysfunction has cascading effects on protein homeostasis throughout the cell. In neurodegenerative diseases, where proteostatic mechanisms are generally compromised, EEF1A1 dysfunction may accelerate the aggregation and accumulation of disease-associated proteins.
The connections between EEF1A1 and protein degradation pathways, including the ubiquitin-proteasome system and autophagy, are particularly relevant to disease pathogenesis. EEF1A1 itself can be subject to ubiquitination and degradation, and alterations in EEF1A1 levels affect the degradation of other proteins. This bidirectional relationship between translation and degradation is a key feature of proteostatic network function.
The recognition of translational dysregulation as a common feature of neurodegenerative diseases has opened new therapeutic avenues. Strategies targeting translation initiation, such as mTOR inhibitors and eIF2B activators, have shown promise in preclinical models and are advancing in clinical trials. Targeting EEF1A1 directly or indirectly through upstream regulators may provide benefits by restoring translational homeostasis in affected neurons.
Small molecules that enhance eEF1A1 function or protect it from pathological modifications represent potential therapeutic approaches. Similarly, interventions that improve the cellular capacity for RQC and stress granule dynamics may address downstream consequences of EEF1A1 dysfunction. The complexity of EEF1A1's functions requires careful consideration of potential side effects, as complete inhibition of EEF1A1 would be profoundly disruptive to cellular viability.
EEF1A1 and its modifications may serve as biomarkers for neurodegenerative disease diagnosis, progression monitoring, or treatment response. Cerebrospinal fluid levels of EEF1A1 and associated proteins have been investigated as potential biomarkers in Alzheimer's and Parkinson's disease. The development of robust biomarker assays for EEF1A1-related parameters could facilitate earlier diagnosis and better monitoring of disease progression.
EEF1A1 connects to numerous other topics within NeuroWiki:
Key molecular relationships involving eef1a1 from the SciDEX knowledge graph:
The following diagram shows the key molecular relationships involving eef1a1 discovered through SciDEX knowledge graph analysis: